{"transactions":[{"id":729054,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock options (right to buy)","published_at":"2026-06-23T21:21:59.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":14950,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027."}],"balance_after":14950,"derivative":{"exercise_price":34.16,"expiration_date":"2036-06-18","underlying":"Common stock","underlying_shares":14950},"source":{"system":"sec-edgar","filing":"0001439222-26-000099","document":"wk-form4_1782249717.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000099/wk-form4_1782249717.xml","form_type":"4"}},{"id":729053,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2026-06-23T21:21:59.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":2927,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":2927,"derivative":{"underlying":"Common stock","underlying_shares":2927},"source":{"system":"sec-edgar","filing":"0001439222-26-000099","document":"wk-form4_1782249717.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000099/wk-form4_1782249717.xml","form_type":"4"}},{"id":729052,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2026-06-23T21:21:59.000Z","date":"2026-06-18","kind":"exercise","planned":false,"acquired":false,"shares":2816,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":2816},"source":{"system":"sec-edgar","filing":"0001439222-26-000099","document":"wk-form4_1782249717.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000099/wk-form4_1782249717.xml","form_type":"4"}},{"id":729051,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2026-06-23T21:21:59.000Z","date":"2026-06-18","kind":"exercise","planned":false,"acquired":true,"shares":2816,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":19848,"source":{"system":"sec-edgar","filing":"0001439222-26-000099","document":"wk-form4_1782249717.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000099/wk-form4_1782249717.xml","form_type":"4"}},{"id":735074,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-17T23:43:47.000Z","date":"2026-06-12","kind":"grant","planned":false,"acquired":true,"shares":7000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in four equal quarterly installments measured from the date of grant."}],"balance_after":7000,"derivative":{"exercise_price":7.13,"expiration_date":"2036-06-11","underlying":"Common Stock","underlying_shares":7000},"source":{"system":"sec-edgar","filing":"0001646395-26-000002","document":"form4-06172026_110643.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921299/000164639526000002/form4-06172026_110643.xml","form_type":"4"}},{"id":750013,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-04T22:07:53.000Z","date":"2026-06-02","kind":"grant","planned":false,"acquired":true,"shares":7490,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units granted on June 2, 2026. Price not applicable."}],"balance_after":35500,"source":{"system":"sec-edgar","filing":"0001628280-26-040918","document":"wk-form4_1780610870.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000162828026040918/wk-form4_1780610870.xml","form_type":"4"}},{"id":758920,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-29T20:21:29.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option vest on the earlier of (i) the one year anniversary of May 27, 2026 or (ii) immediately prior to the next Annual Meeting following May 27, 2026."}],"balance_after":80000,"derivative":{"exercise_price":1.86,"expiration_date":"2036-05-26","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001610717-26-000169","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071726000169/form4.xml","form_type":"4"}},{"id":1103657,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2025-06-23T20:21:21.000Z","date":"2025-06-20","kind":"exercise","planned":false,"acquired":false,"shares":2120,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units were granted on June 20, 2024. The shares underlying the stock units vest in full on June 20, 2025. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units were granted on June 20, 2024. The shares underlying the stock units vest in full on June 20, 2025. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":2120},"source":{"system":"sec-edgar","filing":"0001439222-25-000053","document":"wk-form4_1750710074.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922225000053/wk-form4_1750710074.xml","form_type":"4"}},{"id":1103656,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock options (right to buy)","published_at":"2025-06-23T20:21:21.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":15768,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These options were granted on June 18, 2025. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2026."}],"balance_after":15768,"derivative":{"exercise_price":35.5,"expiration_date":"2035-06-18","underlying":"Common stock","underlying_shares":15768},"source":{"system":"sec-edgar","filing":"0001439222-25-000053","document":"wk-form4_1750710074.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922225000053/wk-form4_1750710074.xml","form_type":"4"}},{"id":1103655,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2025-06-23T20:21:21.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":2816,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":2816,"derivative":{"underlying":"Common stock","underlying_shares":2816},"source":{"system":"sec-edgar","filing":"0001439222-25-000053","document":"wk-form4_1750710074.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922225000053/wk-form4_1750710074.xml","form_type":"4"}},{"id":1103654,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2025-06-23T20:21:21.000Z","date":"2025-06-20","kind":"exercise","planned":false,"acquired":true,"shares":2120,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":17032,"source":{"system":"sec-edgar","filing":"0001439222-25-000053","document":"wk-form4_1750710074.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922225000053/wk-form4_1750710074.xml","form_type":"4"}},{"id":1120347,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-06T20:20:49.000Z","date":"2025-06-04","kind":"grant","planned":false,"acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest on the earlier of four equal quarterly installments measured from the date of grant or the date of the next annual meeting of stockholders, subject to the reporting person's continued service at each applicable vest date."}],"balance_after":120000,"derivative":{"exercise_price":0.3051,"expiration_date":"2035-06-03","underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0001415889-25-015989","document":"form4-06062025_080642.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921299/000141588925015989/form4-06062025_080642.xml","form_type":"4"}},{"id":1129423,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-30T22:30:22.000Z","date":"2025-05-28","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"100% of the shares subject to the option vest on the earlier of (i) the one year anniversary of May 28, 2025 or (ii) immediately prior to the next Annual Meeting following May 28, 2025."}],"balance_after":80000,"derivative":{"exercise_price":0.72,"expiration_date":"2035-05-27","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0000950170-25-079919","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025079919/ownership.xml","form_type":"4"}},{"id":1129422,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-30T22:30:22.000Z","date":"2025-05-28","kind":"grant","planned":false,"acquired":true,"shares":28571,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the \"Repricing\") of the outstanding stock options held by members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 3, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option is fully vested and exercisable."}],"balance_after":28571,"derivative":{"exercise_price":0.72,"expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":28571},"source":{"system":"sec-edgar","filing":"0000950170-25-079919","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025079919/ownership.xml","form_type":"4"}},{"id":1129421,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-30T22:30:22.000Z","date":"2025-05-28","kind":"grant","planned":false,"acquired":true,"shares":27802,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the \"Repricing\") of the outstanding stock options held by members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 3, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option is fully vested and exercisable."}],"balance_after":27802,"derivative":{"exercise_price":0.72,"expiration_date":"2033-09-14","underlying":"Common Stock","underlying_shares":27802},"source":{"system":"sec-edgar","filing":"0000950170-25-079919","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025079919/ownership.xml","form_type":"4"}},{"id":1129420,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-30T22:30:22.000Z","date":"2025-05-28","kind":"grant","planned":false,"acquired":true,"shares":95586,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the \"Repricing\") of the outstanding stock options held by members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 3, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option is fully vested and exercisable."}],"balance_after":95586,"derivative":{"exercise_price":0.72,"expiration_date":"2031-04-23","underlying":"Common Stock","underlying_shares":95586},"source":{"system":"sec-edgar","filing":"0000950170-25-079919","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025079919/ownership.xml","form_type":"4"}},{"id":1129419,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-30T22:30:22.000Z","date":"2025-05-28","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":28571,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 3, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":1.69,"expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":28571},"source":{"system":"sec-edgar","filing":"0000950170-25-079919","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025079919/ownership.xml","form_type":"4"}},{"id":1129418,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-30T22:30:22.000Z","date":"2025-05-28","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":27802,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 3, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":1.69,"expiration_date":"2033-09-14","underlying":"Common Stock","underlying_shares":27802},"source":{"system":"sec-edgar","filing":"0000950170-25-079919","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025079919/ownership.xml","form_type":"4"}},{"id":1129417,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-30T22:30:22.000Z","date":"2025-05-28","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":95586,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 3, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":1.69,"expiration_date":"2031-04-23","underlying":"Common Stock","underlying_shares":95586},"source":{"system":"sec-edgar","filing":"0000950170-25-079919","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025079919/ownership.xml","form_type":"4"}},{"id":1137824,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-22T20:57:38.000Z","date":"2025-05-20","kind":"grant","planned":false,"acquired":true,"shares":6650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units granted on May 20, 2025. Price not applicable."}],"balance_after":28010,"source":{"system":"sec-edgar","filing":"0001048477-25-000072","document":"wk-form4_1747947452.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000104847725000072/wk-form4_1747947452.xml","form_type":"4"}},{"id":1264110,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-18T21:30:08.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":28571,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Effective February 13, 2025, subject to and contingent on the approval by the Issuer's stockholders, the Board approved an option repricing with an exercise price of $1.69 per share (the \"Repricing\") of the outstanding stock options held by members of the Board, certain employees and other service providers, provided that if the requisite approval of the Issuer's stockholders is not obtained, the Repricing will be void and the terms of each repriced option shall continue to be subject to its original terms and conditions, including, without limitation, the per share exercise price. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"100% of the shares subject to the option shall vest on the earlier of (i) one year anniversary of June 13, 2024 or (ii) immediately prior to the next Annual Meeting following June 13, 2024."}],"balance_after":28571,"derivative":{"exercise_price":1.69,"expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":28571},"source":{"system":"sec-edgar","filing":"0000950170-25-022327","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025022327/ownership.xml","form_type":"4"}},{"id":1264109,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-18T21:30:08.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":27802,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Effective February 13, 2025, subject to and contingent on the approval by the Issuer's stockholders, the Board approved an option repricing with an exercise price of $1.69 per share (the \"Repricing\") of the outstanding stock options held by members of the Board, certain employees and other service providers, provided that if the requisite approval of the Issuer's stockholders is not obtained, the Repricing will be void and the terms of each repriced option shall continue to be subject to its original terms and conditions, including, without limitation, the per share exercise price. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option is fully vested and exercisable."}],"balance_after":27802,"derivative":{"exercise_price":1.69,"expiration_date":"2033-09-14","underlying":"Common Stock","underlying_shares":27802},"source":{"system":"sec-edgar","filing":"0000950170-25-022327","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025022327/ownership.xml","form_type":"4"}},{"id":1264108,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-18T21:30:08.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":95586,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Effective February 13, 2025, subject to and contingent on the approval by the Issuer's stockholders, the Board approved an option repricing with an exercise price of $1.69 per share (the \"Repricing\") of the outstanding stock options held by members of the Board, certain employees and other service providers, provided that if the requisite approval of the Issuer's stockholders is not obtained, the Repricing will be void and the terms of each repriced option shall continue to be subject to its original terms and conditions, including, without limitation, the per share exercise price. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option is fully vested and exercisable."}],"balance_after":95586,"derivative":{"exercise_price":1.69,"expiration_date":"2031-04-23","underlying":"Common Stock","underlying_shares":95586},"source":{"system":"sec-edgar","filing":"0000950170-25-022327","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025022327/ownership.xml","form_type":"4"}},{"id":1264107,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-18T21:30:08.000Z","date":"2025-02-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":28571,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"100% of the shares subject to the option shall vest on the earlier of (i) one year anniversary of June 13, 2024 or (ii) immediately prior to the next Annual Meeting following June 13, 2024."}],"balance_after":0,"derivative":{"exercise_price":9.95,"expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":28571},"source":{"system":"sec-edgar","filing":"0000950170-25-022327","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025022327/ownership.xml","form_type":"4"}},{"id":1264106,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-18T21:30:08.000Z","date":"2025-02-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":27802,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":17,"expiration_date":"2033-09-14","underlying":"Common Stock","underlying_shares":27802},"source":{"system":"sec-edgar","filing":"0000950170-25-022327","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025022327/ownership.xml","form_type":"4"}},{"id":1264105,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-18T21:30:08.000Z","date":"2025-02-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":95586,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":2.51,"expiration_date":"2031-04-23","underlying":"Common Stock","underlying_shares":95586},"source":{"system":"sec-edgar","filing":"0000950170-25-022327","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025022327/ownership.xml","form_type":"4"}},{"id":1470591,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock options (right to buy)","published_at":"2024-06-24T20:10:01.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":11774,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on June 20, 2024. The shares underlying this option vest as to 100% of the underlying shares on June 20, 2025."}],"balance_after":11774,"derivative":{"exercise_price":42.45,"expiration_date":"2034-06-20","underlying":"Common stock","underlying_shares":11774},"source":{"system":"sec-edgar","filing":"0001439222-24-000104","document":"wk-form4_1719259794.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922224000104/wk-form4_1719259794.xml","form_type":"4"}},{"id":1470590,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2024-06-24T20:10:01.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":2120,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on June 20, 2024. The shares underlying the stock units will vest in full on June 20, 2025. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on June 20, 2024. The shares underlying the stock units will vest in full on June 20, 2025. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":2120,"derivative":{"underlying":"Common stock","underlying_shares":2120},"source":{"system":"sec-edgar","filing":"0001439222-24-000104","document":"wk-form4_1719259794.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922224000104/wk-form4_1719259794.xml","form_type":"4"}},{"id":1477202,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2024-06-17T21:19:27.000Z","date":"2024-06-13","kind":"exercise","planned":false,"acquired":false,"shares":3388,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on June 13, 2023. The shares underlying the stock units vest in full on June 13, 2024. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on June 13, 2023. The shares underlying the stock units vest in full on June 13, 2024. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":3388},"source":{"system":"sec-edgar","filing":"0001439222-24-000081","document":"wk-form4_1718659159.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922224000081/wk-form4_1718659159.xml","form_type":"4"}},{"id":1477201,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2024-06-17T21:19:27.000Z","date":"2024-06-13","kind":"exercise","planned":false,"acquired":true,"shares":3388,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":14912,"source":{"system":"sec-edgar","filing":"0001439222-24-000081","document":"wk-form4_1718659159.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922224000081/wk-form4_1718659159.xml","form_type":"4"}},{"id":1479380,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-14T20:18:00.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":28571,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"100% of the shares subject to the option shall vest on the earlier of (i) one year anniversary of June 13, 2024 or (ii) immediately prior to the next Annual Meeting following June 13, 2024."}],"balance_after":28571,"derivative":{"exercise_price":9.95,"expiration_date":"2034-06-12","underlying":"Common Stock","underlying_shares":28571},"source":{"system":"sec-edgar","filing":"0001610717-24-000338","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071724000338/form4.xml","form_type":"4"}},{"id":1479379,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-06-14T20:18:00.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":20100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Constitute restricted stock units (\"RSUs\") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the earlier of (i) one year anniversary of June 13, 2024 or (ii) immediately prior to the next Annual Meeting following June 13, 2024."}],"balance_after":20100,"source":{"system":"sec-edgar","filing":"0001610717-24-000338","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071724000338/form4.xml","form_type":"4"}},{"id":1488971,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-07T00:00:15.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options vest on the earlier of June 16, 2025 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date."}],"balance_after":70000,"derivative":{"exercise_price":1.21,"expiration_date":"2034-06-04","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001415889-24-015857","document":"form4-06062024_080612.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921299/000141588924015857/form4-06062024_080612.xml","form_type":"4"}},{"id":1504168,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-23T21:30:39.000Z","date":"2024-05-21","kind":"grant","planned":false,"acquired":true,"shares":4720,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units granted on May 21, 2024. Price not applicable."}],"balance_after":21360,"source":{"system":"sec-edgar","filing":"0001048477-24-000104","document":"wk-form4_1716499826.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000104847724000104/wk-form4_1716499826.xml","form_type":"4"}},{"id":1779110,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-09-18T21:50:21.000Z","date":"2023-09-14","kind":"grant","planned":false,"acquired":true,"shares":27802,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option shall vest and become exercisable on the date of the 2024 Annual Meeting, subject to the Reporting Person continuing in service on the Board through such vesting date."}],"balance_after":27802,"derivative":{"exercise_price":17,"expiration_date":"2033-09-13","underlying":"Common Stock","underlying_shares":27802},"source":{"system":"sec-edgar","filing":"0001610717-23-000281","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071723000281/form4.xml","form_type":"4"}},{"id":1845093,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock unit","published_at":"2023-06-23T20:37:26.000Z","date":"2023-06-21","kind":"exercise","planned":false,"acquired":false,"shares":4975,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on June 21, 2022. The shares underlying the stock units will vest in full on June 21, 2023. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on June 21, 2022. The shares underlying the stock units will vest in full on June 21, 2023. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":4975},"source":{"system":"sec-edgar","filing":"0001439222-23-000095","document":"wk-form4_1687552637.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922223000095/wk-form4_1687552637.xml","form_type":"4"}},{"id":1845092,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2023-06-23T20:37:26.000Z","date":"2023-06-21","kind":"exercise","planned":false,"acquired":true,"shares":4975,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":11524,"source":{"system":"sec-edgar","filing":"0001439222-23-000095","document":"wk-form4_1687552637.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922223000095/wk-form4_1687552637.xml","form_type":"4"}},{"id":1854211,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock options (right to buy)","published_at":"2023-06-15T20:23:43.000Z","date":"2023-06-13","kind":"grant","planned":false,"acquired":true,"shares":18958,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on June 13, 2023. The shares underlying this option vest as to 100% of the underlying shares on June 13, 2024."}],"balance_after":18958,"derivative":{"exercise_price":26.56,"expiration_date":"2033-06-13","underlying":"Common stock","underlying_shares":18958},"source":{"system":"sec-edgar","filing":"0001439222-23-000077","document":"wk-form4_1686860613.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922223000077/wk-form4_1686860613.xml","form_type":"4"}},{"id":1854210,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2023-06-15T20:23:43.000Z","date":"2023-06-13","kind":"grant","planned":false,"acquired":true,"shares":3388,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on June 13, 2023. The shares underlying the stock units will vest in full on June 13, 2024. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on June 13, 2023. The shares underlying the stock units will vest in full on June 13, 2024. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":3388,"derivative":{"underlying":"Common stock","underlying_shares":3388},"source":{"system":"sec-edgar","filing":"0001439222-23-000077","document":"wk-form4_1686860613.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922223000077/wk-form4_1686860613.xml","form_type":"4"}},{"id":1861281,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-09T23:54:20.000Z","date":"2023-06-07","kind":"grant","planned":true,"acquired":true,"shares":12666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Options vest on the earlier of June 7, 2024 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date."}],"balance_after":12666,"derivative":{"exercise_price":17.13,"expiration_date":"2033-06-06","underlying":"Common Stock","underlying_shares":12666},"source":{"system":"sec-edgar","filing":"0001209191-23-036078","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919123036078/doc4.xml","form_type":"4"}},{"id":1861280,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-09T23:54:20.000Z","date":"2023-06-08","kind":"sale","planned":true,"acquired":false,"shares":6225,"price":17.68,"value":110058.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares sold by the reporting person (pursuant to a 10b5-1 trading plan dated March 3, 2023) to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Price reported is a weighted-average sales price. The shares were sold at prices ranging from $17.48 to $17.865. The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":31501,"source":{"system":"sec-edgar","filing":"0001209191-23-036078","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919123036078/doc4.xml","form_type":"4"}},{"id":1861279,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-09T23:54:20.000Z","date":"2023-06-08","kind":"sale","planned":true,"acquired":false,"shares":2295,"price":16.79,"value":38533.05,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares sold by the reporting person (pursuant to a 10b5-1 trading plan dated March 3, 2023) to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Price reported is a weighted-average sales price. The shares were sold at prices ranging from $16.48 to $17.31. The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":37726,"source":{"system":"sec-edgar","filing":"0001209191-23-036078","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919123036078/doc4.xml","form_type":"4"}},{"id":1861278,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-09T23:54:20.000Z","date":"2023-06-07","kind":"grant","planned":true,"acquired":true,"shares":8289,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units that vest on the earlier of June 7, 2024 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date."}],"balance_after":40021,"source":{"system":"sec-edgar","filing":"0001209191-23-036078","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919123036078/doc4.xml","form_type":"4"}},{"id":1880115,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-24T22:26:19.000Z","date":"2023-05-23","kind":"grant","planned":false,"acquired":true,"shares":4190,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units granted on May 23, 2023. Price not applicable."}],"balance_after":16640,"source":{"system":"sec-edgar","filing":"0001209191-23-031970","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000120919123031970/doc4.xml","form_type":"4"}},{"id":2222983,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock options (right to buy)","published_at":"2022-06-23T20:10:25.000Z","date":"2022-06-21","kind":"grant","acquired":true,"shares":29307,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on June 21, 2022. The shares underlying this option vest as to 100% of the underlying shares on June 21, 2023."}],"balance_after":29307,"derivative":{"exercise_price":18.09,"expiration_date":"2032-06-21","underlying":"Common stock","underlying_shares":29307},"source":{"system":"sec-edgar","filing":"0001439222-22-000063","document":"wf-form4_165601500669941.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922222000063/wf-form4_165601500669941.xml","form_type":"4"}},{"id":2222982,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock unit","published_at":"2022-06-23T20:10:25.000Z","date":"2022-06-21","kind":"grant","acquired":true,"shares":4975,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on June 21, 2022. The shares underlying the stock units will vest in full on June 21, 2023. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on June 21, 2022. The shares underlying the stock units will vest in full on June 21, 2023. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":4975,"derivative":{"underlying":"Common stock","underlying_shares":4975},"source":{"system":"sec-edgar","filing":"0001439222-22-000063","document":"wf-form4_165601500669941.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922222000063/wf-form4_165601500669941.xml","form_type":"4"}},{"id":2226091,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-22T01:13:16.000Z","date":"2022-06-16","kind":"grant","acquired":true,"shares":25684,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Options vest on the earlier of June 16, 2023 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date."}],"balance_after":25684,"derivative":{"exercise_price":9,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":25684},"source":{"system":"sec-edgar","filing":"0001209191-22-038616","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919122038616/doc4.xml","form_type":"4"}},{"id":2226090,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-22T01:13:16.000Z","date":"2022-06-16","kind":"grant","acquired":true,"shares":15777,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units that vest on the earlier of June 16, 2023 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date."}],"balance_after":31732,"source":{"system":"sec-edgar","filing":"0001209191-22-038616","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919122038616/doc4.xml","form_type":"4"}},{"id":2255593,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-27T00:57:43.000Z","date":"2022-05-24","kind":"grant","acquired":true,"shares":4980,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units granted on May 24, 2022.  Price not applicable."}],"balance_after":12450,"source":{"system":"sec-edgar","filing":"0001567619-22-011792","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761922011792/doc1.xml","form_type":"4"}},{"id":2258109,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock unit","published_at":"2022-05-24T20:11:13.000Z","date":"2022-05-20","kind":"exercise","acquired":false,"shares":1585,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on May 20, 2021. The shares underlying the stock units will vest in full on May 20, 2022. Vested shares will be delivered to the reporting person within three business days after such shares become vested"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on May 20, 2021. The shares underlying the stock units will vest in full on May 20, 2022. Vested shares will be delivered to the reporting person within three business days after such shares become vested"}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":1585},"source":{"system":"sec-edgar","filing":"0001439222-22-000050","document":"wf-form4_165342305911473.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922222000050/wf-form4_165342305911473.xml","form_type":"4"}},{"id":2258108,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2022-05-24T20:11:13.000Z","date":"2022-05-20","kind":"exercise","acquired":true,"shares":1585,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":6549,"source":{"system":"sec-edgar","filing":"0001439222-22-000050","document":"wf-form4_165342305911473.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922222000050/wf-form4_165342305911473.xml","form_type":"4"}},{"id":2686288,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2021-06-02T20:06:50.000Z","date":"2021-05-28","kind":"exercise","acquired":false,"shares":1686,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on May 28, 2020. The shares underlying the stock units will vest in full on May 28, 2021. Vested shares will be delivered to the reporting person within three businessdays after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on May 28, 2020. The shares underlying the stock units will vest in full on May 28, 2021. Vested shares will be delivered to the reporting person within three businessdays after such shares become vested."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":1686},"source":{"system":"sec-edgar","filing":"0001439222-21-000049","document":"wf-form4_162266438962941.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922221000049/wf-form4_162266438962941.xml","form_type":"4"}},{"id":2686287,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2021-06-02T20:06:50.000Z","date":"2021-05-28","kind":"exercise","acquired":true,"shares":1686,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":4964,"source":{"system":"sec-edgar","filing":"0001439222-21-000049","document":"wf-form4_162266438962941.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922221000049/wf-form4_162266438962941.xml","form_type":"4"}},{"id":2692020,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-28T23:05:54.000Z","date":"2021-05-26","kind":"grant","acquired":true,"shares":7800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Options vest on the earlier of May 26, 2022 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date."}],"balance_after":7800,"derivative":{"exercise_price":20.86,"expiration_date":"2031-05-25","underlying":"Common Stock","underlying_shares":7800},"source":{"system":"sec-edgar","filing":"0001209191-21-036678","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919121036678/doc4.xml","form_type":"4"}},{"id":2692019,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-28T23:05:54.000Z","date":"2021-05-26","kind":"grant","acquired":true,"shares":4700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units that vest on the earlier of May 26, 2022 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date."}],"balance_after":15955,"source":{"system":"sec-edgar","filing":"0001209191-21-036678","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919121036678/doc4.xml","form_type":"4"}},{"id":2693920,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-27T21:57:08.000Z","date":"2021-05-25","kind":"grant","acquired":true,"shares":5120,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units granted on May 25, 2021.  Price not applicable."}],"balance_after":7470,"source":{"system":"sec-edgar","filing":"0001567619-21-011306","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761921011306/doc1.xml","form_type":"4"}},{"id":2698748,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock options (right to buy)","published_at":"2021-05-24T20:44:00.000Z","date":"2021-05-20","kind":"grant","acquired":true,"shares":8888,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on May 20, 2021. The shares underlying this option vest as to 100% of the underlying shares on May 20, 2022."}],"balance_after":8888,"derivative":{"exercise_price":56.76,"expiration_date":"2031-05-20","underlying":"Common stock","underlying_shares":8888},"source":{"system":"sec-edgar","filing":"0001439222-21-000042","document":"wf-form4_162188902273056.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922221000042/wf-form4_162188902273056.xml","form_type":"4"}},{"id":2698747,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock unit","published_at":"2021-05-24T20:44:00.000Z","date":"2021-05-20","kind":"grant","acquired":true,"shares":1585,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on May 20, 2021. The shares underlying the stock units will vest in full on May 20, 2022. Vested shares will be delivered to the reporting person within three business days after such shares become vested"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on May 20, 2021. The shares underlying the stock units will vest in full on May 20, 2022. Vested shares will be delivered to the reporting person within three business days after such shares become vested"}],"balance_after":1585,"derivative":{"underlying":"Common stock","underlying_shares":1585},"source":{"system":"sec-edgar","filing":"0001439222-21-000042","document":"wf-form4_162188902273056.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922221000042/wf-form4_162188902273056.xml","form_type":"4"}},{"id":2846857,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-19T22:28:59.000Z","date":"2021-02-17","kind":"grant","acquired":true,"shares":2350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units granted on February 17, 2021 represent a pro rata share of the 2020 annual award for independent directors and vest on the date immediately prior to the date of the Company's next regular annual meeting of stockholders, the same vesting date for the 2020 annual award for all other independent directors."}],"balance_after":2350,"source":{"system":"sec-edgar","filing":"0001567619-21-004525","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761921004525/doc1.xml","form_type":"4"}},{"id":3119297,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-09T00:27:43.000Z","date":"2020-06-04","kind":"grant","acquired":true,"shares":7800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Options vest on the earlier of June 4, 2021 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date."}],"balance_after":7800,"derivative":{"exercise_price":32.69,"expiration_date":"2030-06-03","underlying":"Common Stock","underlying_shares":7800},"source":{"system":"sec-edgar","filing":"0001209191-20-035150","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919120035150/doc4.xml","form_type":"4"}},{"id":3119296,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-09T00:27:43.000Z","date":"2020-06-04","kind":"grant","acquired":true,"shares":4700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units that vest on the earlier of June 4, 2021 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date."}],"balance_after":11255,"source":{"system":"sec-edgar","filing":"0001209191-20-035150","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919120035150/doc4.xml","form_type":"4"}},{"id":3128948,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2020-06-01T21:12:17.000Z","date":"2020-05-29","kind":"exercise","acquired":false,"shares":1878,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units were granted on May 29, 2019. The shares underlying the stock units will vest in full on May 29, 2020. Vested shares will be delivered to the reporting person within three businessdays after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units were granted on May 29, 2019. The shares underlying the stock units will vest in full on May 29, 2020. Vested shares will be delivered to the reporting person within three businessdays after such shares become vested."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":1878},"source":{"system":"sec-edgar","filing":"0001439222-20-000049","document":"wf-form4_159104592041995.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922220000049/wf-form4_159104592041995.xml","form_type":"4"}},{"id":3128947,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2020-06-01T21:12:17.000Z","date":"2020-05-28","kind":"grant","acquired":true,"shares":1686,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units were granted on May 28, 2020. The shares underlying the stock units will vest in full on May 28, 2021. Vested shares will be delivered to the reporting person within three businessdays after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units were granted on May 28, 2020. The shares underlying the stock units will vest in full on May 28, 2021. Vested shares will be delivered to the reporting person within three businessdays after such shares become vested."}],"balance_after":1686,"derivative":{"underlying":"Common stock","underlying_shares":1686},"source":{"system":"sec-edgar","filing":"0001439222-20-000049","document":"wf-form4_159104592041995.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922220000049/wf-form4_159104592041995.xml","form_type":"4"}},{"id":3128946,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock options (right to buy)","published_at":"2020-06-01T21:12:17.000Z","date":"2020-05-28","kind":"grant","acquired":true,"shares":8096,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on May 28, 2020. This option vests as to 100% of the underlying shares on May 28, 2021."}],"balance_after":8096,"derivative":{"exercise_price":53.35,"expiration_date":"2030-05-28","underlying":"Common stock","underlying_shares":8096},"source":{"system":"sec-edgar","filing":"0001439222-20-000049","document":"wf-form4_159104592041995.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922220000049/wf-form4_159104592041995.xml","form_type":"4"}},{"id":3128945,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2020-06-01T21:12:17.000Z","date":"2020-05-29","kind":"exercise","acquired":true,"shares":1878,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."}],"balance_after":3278,"source":{"system":"sec-edgar","filing":"0001439222-20-000049","document":"wf-form4_159104592041995.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922220000049/wf-form4_159104592041995.xml","form_type":"4"}},{"id":3497813,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-07T22:57:11.000Z","date":"2019-06-05","kind":"grant","acquired":true,"shares":7800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Options vest on the earlier of June 5, 2020 or the date of the next annual meeting of stockholders."}],"balance_after":7800,"derivative":{"exercise_price":39.03,"expiration_date":"2029-06-05","underlying":"Common Stock","underlying_shares":7800},"source":{"system":"sec-edgar","filing":"0001209191-19-035652","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919119035652/doc4.xml","form_type":"4"}},{"id":3497812,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-07T22:57:11.000Z","date":"2019-06-05","kind":"grant","acquired":true,"shares":4700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units that vest on the earlier of June 5, 2020 or the date of the next annual meeting of stockholders."}],"balance_after":6555,"source":{"system":"sec-edgar","filing":"0001209191-19-035652","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919119035652/doc4.xml","form_type":"4"}},{"id":3506282,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2019-05-31T20:07:40.000Z","date":"2019-05-31","kind":"exercise","acquired":false,"shares":1400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units were granted on May 31, 2018. The shares underlying the stock units vested in full on May 31, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units were granted on May 31, 2018. The shares underlying the stock units vested in full on May 31, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":1400},"source":{"system":"sec-edgar","filing":"0001209191-19-033622","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919119033622/doc4.xml","form_type":"4"}},{"id":3506281,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2019-05-31T20:07:40.000Z","date":"2019-05-29","kind":"grant","acquired":true,"shares":1878,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units were granted on May 29, 2019. The shares underlying the stock units will vest in full on May 29, 2020. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units were granted on May 29, 2019. The shares underlying the stock units will vest in full on May 29, 2020. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":1878,"derivative":{"underlying":"Common stock","underlying_shares":1878},"source":{"system":"sec-edgar","filing":"0001209191-19-033622","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919119033622/doc4.xml","form_type":"4"}},{"id":3506280,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2019-05-31T20:07:40.000Z","date":"2019-05-29","kind":"grant","acquired":true,"shares":8919,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on May 29, 2019. The shares underlying this option vest as to 100% of the underlying shares on May 29, 2020."}],"balance_after":8919,"derivative":{"exercise_price":47.91,"expiration_date":"2029-05-29","underlying":"Common stock","underlying_shares":8919},"source":{"system":"sec-edgar","filing":"0001209191-19-033622","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919119033622/doc4.xml","form_type":"4"}},{"id":3506279,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2019-05-31T20:07:40.000Z","date":"2019-05-31","kind":"exercise","acquired":true,"shares":1400,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."}],"balance_after":1400,"source":{"system":"sec-edgar","filing":"0001209191-19-033622","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919119033622/doc4.xml","form_type":"4"}},{"id":3670983,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-02-08T00:54:50.000Z","date":"2018-12-06","kind":"grant","acquired":true,"shares":3008,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Options vest on the earlier of June 6, 2019 or the date of next annual meeting of stockholders."}],"balance_after":3008,"derivative":{"exercise_price":40.93,"expiration_date":"2028-12-06","underlying":"Common Stock","underlying_shares":3008},"source":{"system":"sec-edgar","filing":"0001209191-19-008296","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919119008296/doc4a.xml","form_type":"4/A","original_submission_date":"2018-12-07"}},{"id":3670982,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-02-08T00:54:50.000Z","date":"2018-12-06","kind":"grant","acquired":true,"shares":10400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Option vests quarterly over three years from December 5, 2018."}],"balance_after":10400,"derivative":{"exercise_price":40.93,"expiration_date":"2028-12-06","underlying":"Common Stock","underlying_shares":10400},"source":{"system":"sec-edgar","filing":"0001209191-19-008296","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919119008296/doc4a.xml","form_type":"4/A","original_submission_date":"2018-12-07"}},{"id":3670981,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-02-08T00:54:50.000Z","date":"2018-12-06","kind":"grant","acquired":true,"shares":1855,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units that vest on the earlier of June 6, 2019 or the date of the next annual meeting of stockholders."}],"balance_after":1855,"source":{"system":"sec-edgar","filing":"0001209191-19-008296","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919119008296/doc4a.xml","form_type":"4/A","original_submission_date":"2018-12-07"}},{"id":3740245,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-12-07T23:51:56.000Z","date":"2018-12-05","kind":"grant","acquired":true,"shares":3008,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Options vest on the earlier of June 6, 2019 or the date of next annual meeting of stockholders."}],"balance_after":3008,"derivative":{"exercise_price":41.34,"expiration_date":"2028-12-05","underlying":"Common Stock","underlying_shares":3008},"source":{"system":"sec-edgar","filing":"0001209191-18-061652","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919118061652/doc4.xml","form_type":"4"}},{"id":3740244,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-12-07T23:51:56.000Z","date":"2018-12-05","kind":"grant","acquired":true,"shares":10400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Option vests quarterly over three years from December 5, 2018."}],"balance_after":10400,"derivative":{"exercise_price":41.34,"expiration_date":"2028-12-05","underlying":"Common Stock","underlying_shares":10400},"source":{"system":"sec-edgar","filing":"0001209191-18-061652","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919118061652/doc4.xml","form_type":"4"}},{"id":3740243,"issuer":{"id":7431,"kind":"organization","name":"KYNTRA BIO, INC.","symbol":"KYNB"},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-12-07T23:51:56.000Z","date":"2018-12-05","kind":"grant","acquired":true,"shares":1855,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units that vest on the earlier of June 6, 2019 or the date of the next annual meeting of stockholders."}],"balance_after":1855,"source":{"system":"sec-edgar","filing":"0001209191-18-061652","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/921299/000120919118061652/doc4.xml","form_type":"4"}},{"id":3908244,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2018-06-04T20:23:25.000Z","date":"2018-05-31","kind":"grant","acquired":true,"shares":1400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units were granted on May 31, 2018. The shares underlying the stock units will vest in full on May 31, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units were granted on May 31, 2018. The shares underlying the stock units will vest in full on May 31, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":1400,"derivative":{"underlying":"Common stock","underlying_shares":1400},"source":{"system":"sec-edgar","filing":"0001209191-18-035070","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118035070/doc4.xml","form_type":"4"}},{"id":3908243,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2018-06-04T20:23:25.000Z","date":"2018-05-31","kind":"grant","acquired":true,"shares":5700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on May 31, 2018. The shares underlying this option vest as to 100% of the underlying shares on May 31, 2019."}],"balance_after":5700,"derivative":{"exercise_price":93.5,"expiration_date":"2028-05-30","underlying":"Common stock","underlying_shares":5700},"source":{"system":"sec-edgar","filing":"0001209191-18-035070","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118035070/doc4.xml","form_type":"4"}},{"id":4193089,"issuer":{"id":172709,"kind":"organization","name":"PAREXEL INTERNATIONAL CORP","symbol":"PRXL"},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-10-04T20:22:31.000Z","date":"2017-09-29","kind":"disposition_to_issuer","acquired":false,"shares":6612,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger by and among PAREXEL International Corporation, West Street Parent, LLC and West Street Merger Sub, Inc., dated June 19, 2017 (the \"Merger Agreement\"), whereby, at the effective time of the merger contemplated therein (the \"Effective Time\"), all issued and outstanding shares of the Issuer's common stock were automatically cancelled and converted into the right to receive $88.10 per share in cash without interest (the \"Merger Consideration\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger by and among PAREXEL International Corporation, West Street Parent, LLC and West Street Merger Sub, Inc., dated June 19, 2017 (the \"Merger Agreement\"), whereby, at the effective time of the merger contemplated therein (the \"Effective Time\"), all issued and outstanding shares of the Issuer's common stock were automatically cancelled and converted into the right to receive $88.10 per share in cash without interest (the \"Merger Consideration\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-17-023639","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/799729/000089924317023639/doc4.xml","form_type":"4"}},{"id":4213113,"issuer":{"id":172709,"kind":"organization","name":"PAREXEL INTERNATIONAL CORP","symbol":"PRXL"},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true}}],"security":"Common Stock","published_at":"2017-09-11T14:07:25.000Z","date":"2017-09-08","kind":"grant","acquired":true,"shares":1823,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Shares of restricted stock awarded pursuant to  PAREXEL International Corporation 2015 Stock Incentive Plan."}],"balance_after":6612,"source":{"system":"sec-edgar","filing":"0001127602-17-027248","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/799729/000112760217027248/form4.xml","form_type":"4"}},{"id":4280652,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2017-06-15T21:05:12.000Z","date":"2017-06-13","kind":"grant","acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 13, 2017. The shares underlying this option vest as to 100% of the underlying shares on June 13, 2018."}],"balance_after":8000,"derivative":{"exercise_price":50.73,"expiration_date":"2027-06-12","underlying":"Common stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001209191-17-040191","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919117040191/doc4.xml","form_type":"4"}},{"id":4602278,"issuer":{"id":172709,"kind":"organization","name":"PAREXEL INTERNATIONAL CORP","symbol":"PRXL"},"owners":[{"id":35961,"kind":"person","name":"Ho Maykin","position":1,"cik":"0001646395","reported_name":"Ho Maykin","relationship":{"director":true}}],"security":"Common Stock","published_at":"2016-09-16T10:48:05.000Z","date":"2016-09-15","kind":"grant","acquired":true,"shares":2369,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Shares of restricted stock awarded pursuant to  PAREXEL International Corporation 2015 Stock Incentive Plan."}],"balance_after":4789,"source":{"system":"sec-edgar","filing":"0001127602-16-062581","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/799729/000112760216062581/form4.xml","form_type":"4"}}]}